Skip to main content
Biophytis S.A. logo

Biophytis S.A. — Investor Relations & Filings

Ticker · ALBPS ISIN · FR001400OLP5 LEI · 9695008GIE061NBGU106 PA Professional, scientific and technical activities
Open in API
Filings indexed 546 across all filing types
Latest filing 2023-09-25 Regulatory Filings
Country FR France
Listing PA ALBPS

About Biophytis S.A.

https://www.biophytis.com/en/

Biophytis S.A. is a clinical-stage biotechnology company focused on developing therapeutics to slow degenerative processes associated with aging and improve longevity. The company's primary strategy is centered on treating diseases that impair mobility. Its lead drug candidate, BIO101, is being advanced in late-stage clinical development for multiple age-related conditions. A key program is the SARA Phase 3 trial, the first-ever pivotal study for the treatment of sarcopenia (age-related muscle loss). Additionally, BIO101 is being evaluated in the OBA Phase 2 clinical trial for addressing muscle wasting in patients with obesity. The company aims to preserve muscle function and enhance functional outcomes for patients.

Recent filings

Filing Released Lang Actions
Biophytis and Skyepharma sign a Partnership Agreement for the Production of Sarconeos (BIO101)
Regulatory Filings Classification · 100% confidence The document is a press release dated September 25, 2023, announcing a partnership agreement between Biophytis and Skyepharma for the production of Sarconeos (BIO101). This type of announcement, detailing a significant business development (a partnership/collaboration), does not fit neatly into the specific financial reporting categories like 10-K, ER, or IR. It is a general corporate announcement regarding business operations and strategy. Since it is not a formal regulatory filing like a 10-K, nor a specific announcement like a dividend (DIV) or management change (MANG), the most appropriate general category for significant, non-standard corporate news that doesn't fit elsewhere is 'Regulatory Filings' (RNS), which serves as a broad category for miscellaneous official announcements, or potentially 'Capital/Financing Update' (CAP) if the partnership involved significant capital terms, but here it is primarily operational/developmental. Given the nature of the announcement (partnership for production/development), 'Regulatory Filings' (RNS) is the best fit as a catch-all for important, non-standard corporate news releases.
2023-09-25 English
Biophytis et Skyepharma signent un partenariat pour la production de Sarconeos (BIO101)
Regulatory Filings Classification · 95% confidence The document is a press release dated September 25, 2023, announcing a partnership between Biophytis and Skyepharma regarding the production of regulatory batches of Sarconeos (BIO101) for severe Covid-19, in preparation for market authorization applications. This type of announcement, detailing a strategic business development (partnership for manufacturing/supply chain), does not fit neatly into the specific financial reporting categories (10-K, IR, ER, etc.). It is a general corporate announcement regarding operations and future regulatory steps. Since it is not a formal regulatory filing like a 10-K or a specific financial event like a dividend or earnings release, and it is not a management change (MANG) or director dealing (DIRS), the most appropriate general category for a significant corporate development announcement that doesn't fit elsewhere is Regulatory Filings (RNS), which serves as a broad category for miscellaneous regulatory/corporate news releases.
2023-09-25 French
Biophytis provides an update on its early access programs for Sarconeos (BIO101) in the treatment of severe forms of COVID-19
Regulatory Filings Classification · 95% confidence The document is a press release dated September 19, 2023, providing an update on the company's early access programs for Sarconeos (BIO101) concerning COVID-19 treatment, specifically mentioning responses from the French National Authority for Health (HAS) and plans for resubmission in Q1 2024. It also mentions updates on strategy in Brazil and other countries. This type of communication, detailing regulatory progress, clinical trial updates, and strategic business developments outside of routine financial reporting (like 10-K or IR), is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is an update on regulatory progress and strategy, and not a formal financial report or a transcript, it fits best as an Earnings Release (ER) if it were tied to a reporting period, or a general Regulatory Filing (RNS) if it's a standalone operational update. Given the content focuses heavily on regulatory feedback and future plans rather than just summarizing period financials, RNS is a strong candidate. However, updates on clinical progress and regulatory hurdles are often bundled into ERs or investor updates. Since it is a formal announcement updating stakeholders on key operational and regulatory milestones, and it is not a specific financial report (10-K, IR, MRQ), nor a proxy/dividend notice, it falls under the general category of important company news. Given the options, and that it is a specific, non-financial regulatory/operational update, RNS (Regulatory Filings - general fallback) is appropriate, although ER is also plausible if this was released near a reporting date. I will classify it as RNS as it is a specific regulatory/program update announcement that doesn't fit the other specific categories well, and it is not a short announcement pointing to a full report (RPA).
2023-09-19 English
Biophytis fait le point sur ses programmes d’accès précoce pour Sarconeos (BIO101) dans le traitement des formes sévères de COVID-19
Regulatory Filings Classification · 95% confidence The document is a press release dated September 19, 2023, detailing an update on regulatory progress (specifically regarding 'Autorisation d'Accès Précoce' or Early Access Authorization) for their drug Sarconeos (BIO101) in France and Brazil concerning severe COVID-19 treatment. It discusses receiving feedback from the HAS (Haute Autorité de Santé) and plans to refile the application. This type of announcement, which provides updates on clinical/regulatory strategy and progress without being a full financial report (like 10-K or IR) or a formal regulatory filing attachment, most closely aligns with an 'Earnings Release' (ER) if it were tied to financial results, or a general 'Regulatory Filing' (RNS) if it were a mandatory disclosure. However, given the content focuses heavily on clinical/regulatory strategy updates and is presented as a news announcement, it functions similarly to an Earnings Release (ER) which often includes operational updates, or it could be classified as a general Regulatory Filing (RNS) as it pertains to regulatory interactions. Since it is not a formal financial report, nor a transcript, nor a management discussion, and it is an announcement of operational/regulatory status, 'ER' (Earnings Release, often used broadly for period updates) or 'RNS' (Regulatory Filings/Announcements) are the closest fits. Given the focus on regulatory feedback and future filing plans, 'RNS' (Regulatory Filings) is the most appropriate general category for non-standard, material operational updates that aren't explicitly defined elsewhere. The document length (5867 chars) is substantial enough to not be a simple RPA, but it is clearly an announcement/press release.
2023-09-19 French
Biophytis renforce sa direction avec la nomination de son Chief Business Officer
Board/Management Information Classification · 100% confidence The document is a press release dated September 14, 2023, announcing the appointment of Edouard Bieth as Chief Business Officer and Claudia Ferreira as Medical Director. This type of announcement, detailing changes in senior management or the board of directors, directly corresponds to the definition of 'Board/Management Information'. The document is not a full financial report (10-K or IR), an earnings release (ER), or a proxy statement (DEF 14A/PSI). Therefore, the appropriate classification is MANG.
2023-09-14 French
Biophytis Strengthens its Management Team with the Appointment of its Chief Business Officer
Board/Management Information Classification · 100% confidence The document is a press release dated September 14, 2023, announcing the appointment of Edouard Bieth as Chief Business Officer and Claudia Ferreira as Medical Director. This content directly relates to changes in the company's senior management team and executive committee composition. This aligns perfectly with the definition for Board/Management Information (MANG). It is not an earnings release (ER), a full annual report (10-K), or a general regulatory filing (RNS), as it concerns specific personnel changes.
2023-09-14 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.